Sudarshan Pharma Industries (543828) Q2 2027 earnings summary

Executive summary

• Q2 FY27 consolidated revenue was ₹21,696.93 lakh and profit attributable to owners was ₹808.75 lakh; H1 revenue reached ₹39,138.77 lakh and owner profit ₹1,394.27 lakh.

• Standalone Q2 revenue was ₹20,501.80 lakh and net profit ₹779.51 lakh; H1 net profit was ₹1,383.69 lakh.

Financial highlights

• Consolidated Q2 revenue rose to ₹21,696.93 lakh from ₹16,886.70 lakh YoY; total income was ₹21,890.19 lakh.

• Consolidated Q2 profit before tax was ₹1,080.26 lakh versus ₹422.80 lakh YoY; profit attributable to owners was ₹808.75 lakh versus ₹418.34 lakh.

• Consolidated H1 revenue was ₹39,138.77 lakh and profit before tax ₹1,830.79 lakh; owner profit was ₹1,394.27 lakh.

• Standalone Q2 revenue was ₹20,501.80 lakh versus ₹16,700.63 lakh YoY; net profit was ₹779.51 lakh versus ₹440.03 lakh.

• Consolidated Q2 basic and diluted EPS were ₹0.31 each, versus ₹0.16 in Q2 FY26; H1 EPS was ₹0.54 versus ₹0.32.

Outlook and guidance

• Palghar manufacturing closure is expected to rationalize fixed and operating costs, limit further losses, and redirect resources toward more sustainable, profitable operations.